Next Article in Journal
Spatial Immune Profiling and AI-Based Classifiers Identify Predictors of BCG Therapy Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer
Previous Article in Journal
Conjunctival Squamous Cell Carcinoma: A Clinical Review of Diagnostic Features, Genetics, Current Management and an Update on Targeted and Immunotherapies
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124

by
Bertrand Pourroy
1,
Maria D. Aumente
2,
Christian Koenecke
3,
Martin Stanulla
3,
Andrés J. M. Ferreri
4,
Thais M. Carillo
5,
Madhumita Dandapani
6,
Timothy A. Ritzmann
7,
Pere Barba
8,
Etienne Chatelut
9,
Katrina M. Ingley
10,
Emma Morris
11,
Elisabeth Schorb
12,
Sven Liebig
13,
Stefan Schwartz
13,
Scott C. Howard
14,15,
Ryan Combs
14,
Nicolás Tentoni
14,
Jennifer Lowe
14,
Gabriela Villanueva
14,
Claudia Sampor
14,†,
Miriam Hwang
14,* and
Carmelo Rizzari
16,‡
add Show full author list remove Hide full author list
1
Oncopharma Unit, Hôpitaux Universitaires de Marseille La Timone, 13005 Marseille, France
2
Pharmacy Service, Reina Sofia University Hospital, 14004 Cordoba, Spain
3
Department of Pediatric Hematology and Oncology, University of Hannover, 30167 Hannover, Germany
4
Lymphoma Unit, IRCCS San Raffaele Scientific Institute, 20132 Milano, Italy
5
Pediatric Oncology & Hematology, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain
6
Department of Pediatrics Oncology/Haematology, University of Nottingham, Nottingham NG5 1PB, UK
7
Children’s Brain Tumour Research Centre, University of Nottingham, Nottingham NG7 2UH, UK
8
Hematology Department, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain
9
Department of Pharmacology, Institut Universitaire du Cancer-Oncopole, 31059 Toulouse, France
10
Sarcoma Department, University College London Hospital, London NW1 2PB, UK
11
Pharmacy Cancer Services, University College London Hospital, London NW1 2PB, UK
12
Comprehensive Cancer Center, University of Freiburg, 79106 Freiburg, Germany
13
Department of Hematology, Oncology and Tumor Immunology, Charite Universitätsmedizin, 10117 Berlin, Germany
14
Resonance, Memphis, TN 38104, USA
15
Global Development Office, Hospital Sant Joan de Deu, 08950 Barcelona, Spain
16
Department of Pediatrics, University of Milano-Bicocca, 20126 Milan, Italy
*
Author to whom correspondence should be addressed.
Current address: Pan American Health Organization (PAHO), Washington, DC 20037, USA.
C. Rizzari is the Senior author of this paper and is currently affiliated with Pediatric Hematology and Oncology Unit, IRCCS San Gerardo dei Tinori, 20900 Monza, Italy.
Cancers 2026, 18(6), 941; https://doi.org/10.3390/cancers18060941
Submission received: 26 February 2026 / Accepted: 27 February 2026 / Published: 13 March 2026
(This article belongs to the Section Cancer Epidemiology and Prevention)
Text Correction
There was an error in the original publication [1]. “Percentages presented in the text in the seventh (36.8% vs. 19.0%) and eighth sentences (9.6%; 2.1%) were errors and did not match those in Table 5 of which they were referenced”.
A correction has been made to 3. Results section, 3.3. Impact of Primary Endpoint Occurrence on Clinical Outcomes and Adverse Events subsection, first paragraph, seventh and eighth sentences:
Courses in which DME occurred required significantly longer delays prior to the next course of treatment compared to courses without DME occurrence (Table 5). Hospital LOS for chemotherapy was significantly longer in courses in which DME occurred (5.3 days, IQR 4.2–9.1) compared to those with no DME (4.2 days, IQR 3.7–6.1). Similarly, courses with AKI and DME + AKI required longer hospital LOS compared to courses without AKI and DME + AKI, respectively. The proportion of courses that required rehospitalization for toxicity was smaller in courses with DME (4.0%) compared to those without DME (6.1%); however, the median LOS of rehospitalization for toxicity management was 1.4 days longer in courses with DME. In contrast, courses with AKI occurrence were observed to have a higher incidence (7.8% vs. 5.5%) of rehospitalization but shorter LOS (3.5 days vs. 5.1 days) than those without AKI. However, these differences in rehospitalization were not significant. Methotrexate dose omission in the subsequent course occurred more frequently in courses that experienced DME, AKI, and DME + AKI compared to those that did not: 9.6% vs. 2.1%, 4.9% vs. 2.7%, and 7.5% vs. 2.8%, respectively. Methotrexate dose reduction in the subsequent course was required more frequently in courses with DME (27.8%) than those without DME (17.3%), whereas it was required less frequently in courses with AKI occurrence (12.5%) compared to those without AKI (19.7%).
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Pourroy, B.; Aumente, M.D.; Koenecke, C.; Stanulla, M.; Ferreri, A.J.M.; Murciano-Carillo, T.; Dandapani, M.; Ritzmann, T.A.; Barba, P.; Chatelut, E.; et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Pourroy, B.; Aumente, M.D.; Koenecke, C.; Stanulla, M.; Ferreri, A.J.M.; Carillo, T.M.; Dandapani, M.; Ritzmann, T.A.; Barba, P.; Chatelut, E.; et al. Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124. Cancers 2026, 18, 941. https://doi.org/10.3390/cancers18060941

AMA Style

Pourroy B, Aumente MD, Koenecke C, Stanulla M, Ferreri AJM, Carillo TM, Dandapani M, Ritzmann TA, Barba P, Chatelut E, et al. Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124. Cancers. 2026; 18(6):941. https://doi.org/10.3390/cancers18060941

Chicago/Turabian Style

Pourroy, Bertrand, Maria D. Aumente, Christian Koenecke, Martin Stanulla, Andrés J. M. Ferreri, Thais M. Carillo, Madhumita Dandapani, Timothy A. Ritzmann, Pere Barba, Etienne Chatelut, and et al. 2026. "Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124" Cancers 18, no. 6: 941. https://doi.org/10.3390/cancers18060941

APA Style

Pourroy, B., Aumente, M. D., Koenecke, C., Stanulla, M., Ferreri, A. J. M., Carillo, T. M., Dandapani, M., Ritzmann, T. A., Barba, P., Chatelut, E., Ingley, K. M., Morris, E., Schorb, E., Liebig, S., Schwartz, S., Howard, S. C., Combs, R., Tentoni, N., Lowe, J., ... Rizzari, C. (2026). Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124. Cancers, 18(6), 941. https://doi.org/10.3390/cancers18060941

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop